Salomon & Ludwin
RPRX icon

Salomon & Ludwin’s Royalty Pharma RPRX Stock Holding History

Salomon & Ludwin’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$7.64K Hold
131
– – ﹤0.01% 1397
2026
Q2 		$7.31K Hold
131
– – ﹤0.01% 1712
2026
Q1 		$6.36K Hold
131
– – ﹤0.01% 1694
2025
Q4 		$5.19K Sell
131
-152
-54% -$5.8K ﹤0.01% 1764
2025
Q3 		$10.2K Buy
+283
New +$10.2K ﹤0.01% 1291

Other funds holding RPRX

Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
New South Capital Management
New South Capital Management Memphis, Tennessee $1.53B AUM 36.31% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

Salomon & Ludwin's RPRX Position: Q3 2026 in Review

Salomon & Ludwin held its Royalty Pharma (RPRX) position steady in Q3 2026 at 131 shares worth $7.64K. The position accounts for ﹤0.01% of the portfolio, ranked #1397.

Salomon & Ludwin first reported a position in RPRX in Q3 2025 and has held it in 5 quarters since. The position peaked at $10.2K in Q3 2025. 318 funds tracked by Wall St. Rank hold RPRX as of Q3 2026.

  • Salomon & Ludwin held 131 shares of Royalty Pharma worth $7.64K as of Q3 2026.
  • Salomon & Ludwin left its Royalty Pharma share count unchanged in Q3 2026.
  • Royalty Pharma made up ﹤0.01% of Salomon & Ludwin's portfolio in Q3 2026, its #1397 holding.
  • Salomon & Ludwin first reported a position in Royalty Pharma in Q3 2025 and has held it in 5 quarters since.
  • Salomon & Ludwin's Royalty Pharma position peaked at $10.2K in Q3 2025.
  • 318 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2026.

Based on Salomon & Ludwin's 13F filing for Q3 2026, filed 29 Oct 2026.